Given the intense interest to characterize these multifaceted mechanisms of resistance to anti-EGFR treatment in lung cancer, we used MCPs established from a complex, heterogeneous NSCLC model and assessed how signal dynamics affects response to anti-EGFR treatment across coexisting subpopulations of malignant cells within the tumor microecology. The gene discussed is EGFR; the disease is lung carcinoma.